Treatment with hydroxychloroquine in combination with azithromycin in patients with COVID-19 infection prolongs the QTc interval, [1](#Fn1){ref-type="fn"} according to findings of a French study published in *Mayo Clinic Proceedings*.

Serial 12-lead electrocardiograms in 50 consecutive patients hospitalised with COVID-19 pneumonia in March 2020 were used to investigate the effects of hydroxychloroquine plus azithromycin on QTc interval. Patients received hydroxychloroquine 600 mg/day for 10 days, and azithromycin for 5 days (500mg on day 1 and 250 mg/day for the next 4 days).

The mean QTc interval increased from 408 msec at baseline to 437 msec on day 3 and 465 msec on day 5. The QTc interval increased by over 30 msec in 76% of patients. Treatment was discontinued in six patients because of increased QTc interval, and the interval returned to normal in five of these patients.

Of note, QTc intervals decreased when hydroxychloroquine was continued after azithromycin was stopped. In 20 patients who were discharged from hospital three or more days after the completion of treatment, the QTc interval decreased from 460 msec on day 5 to 427 msec at discharge.

No deaths or clinical heart disorders including arrhythmias or torsades de pointes were reported.

\"These results confirmed that a short duration of treatment with the combination of hydroxychloroquine and azithromycin does modified QTc interval. Nevertheless, in inpatients hospitalised for COVID-19, we did not observe any clinically relevant consequence of these transitory modifications,\" said the investigators.
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